BIII 277CL

Drug Profile

BIII 277CL

Alternative Names: BIII 277; BIII 281CL

Latest Information Update: 10 Mar 1999

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Boehringer Ingelheim
  • Class Anti-ischaemics; Neuroprotectants; Small molecules
  • Mechanism of Action Glutamate receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Stroke

Most Recent Events

  • 10 Mar 1999 Discontinued-Preclinical for Stroke in Germany (Unknown route)
  • 13 Oct 1997 A study has been added to the pharmacodynamics section
  • 18 May 1995 New profile
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top